NEW YORK (GenomeWeb News) — BioSeek said today that it has renewed and expanded an agreement to profile and guide optimization of lead compounds for the drug company UCB.
 
South San Francisco, Calif.-based BioSeek said it will profile selected chemical and biological entities and guide lead optimization of a specific phenotypic hit identified by UCB and characterized using the company’s BioMap screens.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study in JAMA finds that genetic tests might not be able to determine what diet is right for someone seeking to lose weight.

Vampire bats' ability to live off blood is etched in their genomes and gut microbiomes, the Scientist reports.

A genome-wide association study that linked common genetic variants to salivary gland carcinoma risk has been retracted, according to Retraction Watch.

In Genome Biology this week: peopling of the Sahara, epigenetic reprogramming analysis of liverwort, and more.